IPP Bureau
Merck’s KEYTRUDA combo wins key EU backing for bladder cancer treatment
By IPP Bureau - May 25, 2026
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
Datroway wins US nod in aggressive breast cancer subtype
By IPP Bureau - May 25, 2026
Clearance marks major shift beyond chemotherapy
Oral GLP-1 race heats up as Lilly’s Foundayo shines in seniors
By IPP Bureau - May 25, 2026
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
AbbVie scores key EU backing for Hepatitis C drug in push for earlier treatment
By IPP Bureau - May 25, 2026
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
WHO declares Ebola outbreak, Indians advised against travel to affected regions
By IPP Bureau - May 25, 2026
No approved vaccine or specific treatment currently available for Bundibugyo strain Ebola disease
Anupam Rasayan makes foray into pharma with stake in Bliss GVS Pharma
By IPP Bureau - May 25, 2026
Acquisition includes 43.3%–48.2% equity stake and open offer to public shareholders; deal financed through term loan and equity instruments
Akumentis Healthcare appoints Dharnendra Doshi as Senior Vice President
By IPP Bureau - May 25, 2026
Veteran consumer health and FMCG strategist to lead preventive wellness and nutrition portfolio expansion through innovation and modern trade channels
AstraZeneca breast cancer drug wins key EU backing after cutting progression risk by 56%
By IPP Bureau - May 25, 2026
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
Maxivision appoints Surya K as Group Head – Medical Affairs and Quality
By IPP Bureau - May 23, 2026
Surya to lead medical governance, patient safety, clinical excellence, and quality assurance initiatives across the organization’s pan-India network.
Shreevar Kheruka appointed Managing Director at Borosil Limited
By IPP Bureau - May 23, 2026
Kheruka has played a key role in transforming Borosil into a diversified, international consumer-focused enterprise
Fortis Healthcare FY26 revenue crosses Rs. 9,100 crore
By IPP Bureau - May 23, 2026
Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum
Merck doses first patient in Phase 3 trial of novel antibody-drug conjugate for metastatic colorectal cancer
By IPP Bureau - May 23, 2026
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
Eli lilly’s retatrutide delivers up to 30% weight loss in phase 3 trial
By IPP Bureau - May 23, 2026
Clears major obesity endpoints at 80 weeks
Health ministry classifies Pregabalin under Schedule H1 to curb misuse
By IPP Bureau - May 23, 2026
New regulation mandates stricter prescription monitoring, sales record maintenance, and enhanced compliance across the pharmaceutical supply chain
ZIM Laboratories wins European regulatory milestone with anticoagulant approval in Italy
By IPP Bureau - May 23, 2026
The approval was granted by Agenzia Italiana del Farmaco
